- The disease
- Chronic obstructive pulmonary disease (COPD) is a progressive lung condition that makes breathing difficult due to airflow obstruction. It is a leading cause of hospitalisation and home-oxygen dependency worldwide. Post-extubation respiratory failure refers to breathing difficulty that occurs after a patient is removed from mechanical ventilation in an intensive care unit. Both settings can require ongoing respiratory support devices to maintain adequate oxygen delivery and reduce the work of breathing.
- What the asset is trying to do
- AIRVO 3 is a humidified high-flow nasal cannula (HFNC) device that delivers a heated and humidified blend of air and oxygen at high flow rates directly through the nose. Unlike standard oxygen masks or nasal prongs, HFNC systems maintain airway moisture, provide a low level of positive airway pressure, and can reduce the effort required to breathe. The myAirvo 3 is a home-use variant of the platform designed for unsupervised use by COPD patients outside of hospital settings.
- What the trial is measuring, and why it matters
- The lead post-market study (NCT05204888) is evaluating the myAirvo 3 device in COPD patients managed at home, with a primary completion date of January 2027 (per ClinicalTrials.gov NCT05204888). A separate study (NCT06671015) is comparing HFNC against non-invasive ventilation (NIV) in patients at risk of reintubation after extubation, also targeting primary completion in January 2027 (per ClinicalTrials.gov NCT06671015). A respiratory rate validation study (NCT06329609) assessed the accuracy of a respiratory rate algorithm embedded in the AIRVO 3 device in COPD patients and healthy volunteers, with a primary completion date of October 2024 (per ClinicalTrials.gov NCT06329609).
- Efficacy benchmarks in this setting
- In the post-extubation setting, high-flow nasal cannula therapy has been compared with conventional oxygen and NIV in prior randomised trials. Frat et al. (NEJM, 2015) reported that HFNC was associated with lower 90-day mortality compared with conventional oxygen in hypoxaemic patients, though the study was not limited to post-extubation patients. Hernandez et al. (JAMA, 2016) reported that HFNC reduced reintubation rates compared with conventional oxygen in low-risk extubated patients. For home use in COPD, published evidence on HFNC devices varies by patient population and study design. Because the ongoing AIRVO 3 studies are post-market observational or comparative trials still recruiting, any interim figures are not statistically comparable to results from completed randomised controlled trials in these indications.